Pediatric Grand Rounds

FRIDAY, MARCH 10, 2017
8:00 a.m. Storm Eye Auditorium
Topic: “Nutritional Therapy in Pediatric Inflammatory Bowel Disease”
Speaker: Candi Jump, DO, MSED

FRIDAY, MARCH 17, 2017
8:00 a.m. Storm Eye Auditorium
Topic: “Reducing Pediatric Ambulatory Diagnostic Errors: Project RedDE”
Speaker: Michael Rinke, MD, PhD

Volume 7 • Issue 10 • March 9, 2017

Juile Kanter, MD
Associate Professor
Director, Sickle Cell Program
Phone: (843) 792-2957
Email: kanter@musc.edu

For an appointment with a physician, please call: (843) 876-0444

Web Sites:
http://www.musckids.org/
http://musckids.org/pediatrics

Facts FAX team:
Rita Ryan, MD
Linda Howard
Andrew M. Atz, MD
Robin Rose
Amy Hauser, BSN, MBA, MHA, RN, NEA-BC

Stem Cell Transplant a Cure for Sickle Cell Disease

Sickle Cell Disease (SCD) is a hereditary anemia that affects millions of individuals worldwide. It is associated with early mortality and a diminished quality of life, with intermittent episodes of pain that are accompanied by progressive damage to vital organs, such as the lung, brain, spleen and kidney.

Stem cell transplant is the only proven cure for SCD. There are several types of stem cell types: bone marrow, peripheral blood mobilized stem cells, umbilical cord blood.

MUSC has several options for stem cell transplant at this time. We are also part of a new Sickle Transplant Alliance for Research (STAR) Network.

STUDIES:
- STAR- is an active trial that uses HLA matched related hematopoietic stem cell transplantation for children with less severe sickle cell disease. Enrollment for this study will begin in May 2017.
- STRIDE 2 (BMTCTN1503) trial will be looking at stem cell transplant versus standard of care in adolescents and young adults (>16 years of age) with severe sickle cell disease. Enrollment is now open.

Because not all people with sickle cell disease have an available donor, we also hope to identify new methods of transplant using gene therapy or gene editing.
- BlueBird Bio is an active trial in gene therapy using autologous (a patient’s own cells) with Lentiglobin BB305 Vector to insert new hemoglobin A (T87Q) in subjects with severe sickle cell disease >18 years of age.

Please email sicklestrong@musc.edu for any questions or call our Program Manager, Emily Warner at 843-876-8614 for more information.

Announcements:
Need help with a case?
ECHO telementoring conferences to review patients with sickle cell disease at outside institutions are now occurring on the first and third Thursdays of every month. Contact Katherine Williams-Turner if you want to join 843-876-0821

4th Annual Sickle Cell Symposium (co-sponsored by MUSC and COBRA) will be held on Saturday April 22, 2017 from 8:30-1pm in the MUSC Drug Discovery Building Auditorium. Topic: “Preserving Health and Wellness in Individuals with Sickle Cell Disease”.
Who: All medical professionals are welcome to attend and may register by contacting the CME office at cmeoffice@musc.edu or 843-876-1925.